| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
ZWZH-21 inhibited the growth of A549, MCF-7 and HepG2 cells, with IC50 values of 1.66 μM, 2.445 μM and 1.551 μM, respectively [1]. ZWZH-21 (0.4-1.6 μM, 48 h) inhibited temperature-induced degradation of HDAC1/2 in HCT116 cells [1]. ZWZH-21 (0.4-1.6 μM, 48 h) induced the degradation of HDAC1 and HDAC2 proteins, as well as the formation of Ac-H3 and histone H4, in a concentration-dependent manner in HCT116 cells [1]. ZWZH-21 (0.4-1.6 μM, 48 h) inhibited the colony-forming ability of HCT116 and SW480 cells [1]. ZWZH-21 (0.4-2 μM, 48 h) can inhibit the migration of HCT116 and SW480 cells and induce their apoptosis[1]. ZWZH-21 (0.4-2 μM, 48 h) can induce G1 phase arrest in HCT116 and SW480 cells[1].
|
|---|---|
| ln Vivo |
ZWZH-21 (2000 mg/kg, once orally) showed good safety in mice[1]. ZWZH-21 (30-120 mg/kg, gavage, once daily for 14 days) fluorescently labeled the tumor growth of HCT116 human moist carcinoma xenografts[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HCT116 cells Tested Concentrations: 0.4, 0.8, and 1.6 μM Incubation Duration: 48 h Experimental Results: Reduced HDAC1 and HDAC2 protein and increased Ac–H3 and Ac–H4 levels. Apoptosis Analysis[1] Cell Types: HCT116 cells and SW480 cells Tested Concentrations: 0.4, 0.8 and 1.6 μM in HCT116, 0.5, 1 and 2 μM in SW480 cells Incubation Duration: 48 h Experimental Results: Significantly increased the proportion of Annexin V-positive cells. Showed highest apoptotic rates reaching 60.7 % and 40.04 % at low concentrations. Cell Cycle Analysis[1] Cell Types: HCT116 cells and SW480 cells Tested Concentrations: 0.4, 0.8 and 1.6 μM in HCT116, 0.5, 1 and 2 μM in SW480 cells Incubation Duration: 24 h Experimental Results: Demonstrated a dose-dependent accumulation of cells in G1 phase. |
| Animal Protocol |
Animal/Disease Models: Mice bearing HCT116 human colon cancer xenografts[1]
Doses: 30, 60 and 120 mg/kg Route of Administration: Oral gavage, daily for 14 days Experimental Results: Showed no significant body weight changes. Suppressed tumor growth. |
| References |
| Molecular Formula |
C26H22N4O2
|
|---|---|
| Molecular Weight |
422.48
|
| CAS # |
3069195-42-9
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3670 mL | 11.8349 mL | 23.6698 mL | |
| 5 mM | 0.4734 mL | 2.3670 mL | 4.7340 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3670 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
